Atheroregression via Enhanced Reverse Cholesterol Transport
Atheroregression via Enhanced Reverse Cholesterol Transport
批准号:
8819557
负责人:
Henry J. Pownall
金额:
$58.63万
依托单位国家:
美国
项目类别:
财政年份:
1997
资助国家:
美国
项目状态:
已结题
起止时间:
1997-04-01 至 2016-12-31
关键词:
AffinityAnti-Inflammatory AgentsAnti-inflammatoryApolipoprotein A-IApolipoprotein A-IIApolipoprotein EApoproteinsArterial Fatty StreakAtherosclerosisBacterial ProteinsBase CompositionBindingBiochemicalBlood flowCell LineCell modelCellsChemicalsCholesterolCholesterol EstersComplementary therapiesComplexData ReportingDiseaseDockingDoseEthersEtiologyExcisionFutureGoalsHepaticHepatocyteHigh Density Lipoprotein CholesterolHigh Density LipoproteinsHumanIn VitroInjection of therapeutic agentIntestinesIntravenousLDL Cholesterol LipoproteinsLearningLipidsLipoprotein (a)LiverMediatingMethodsModalityModelingMusMyocardial InfarctionPaperPatientsPharmaceutical PreparationsPhosphatidylcholine-Sterol O-AcyltransferasePlasmaPlasma ProteinsProcessPropertyProteinsPublic HealthRadioReactionRecombinantsRecruitment ActivityRecyclingSalineSeriesSiteStagingStreptococcus pyogenesStrokeSurfaceTestingVirulence FactorsWaterarterial lesionbasebile saltscell typechemical kineticshigh riskimprovedin vivolipid disordermacrophagemorphometrymouse modelnonhuman primatenovelopacity factorreceptorreceptor bindingresponsereverse cholesterol transportsuccesssyndecanuptake
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Cholesterol, a water insoluble compound, is a major player in the etiology of atherosclerosis. Cholesterol accumulates in plaques in the arterial wall causing obstructed blood flow leading to heart attacks and strokes. Despite the success of the statin class of cholesterol-lowering drugs, which reduce plasma LDL-cholesterol, there remains an unfulfilled need for complementary therapies that promote the removal of cholesterol from atherosclerotic lesions and its transfer to the liver for disposal. We identified a bacterial protein, serum opacity factor (SOF) that at low doses (0.004 mg) rapidly (6 min) and profoundly reduces by half the plasma cholesterol in mice. On the basis of studies with liver cells, we learned that SOF treatment promotes hepatic cholesterol uptake by multiple receptors that bind to a plasma protein, apolipoprotein E. Our plans are to move these discoveries closer to human therapy by completion of several objectives. The first is to show in primary human hepatocytes that the mechanisms for cholesterol removal are as efficient as they are in hepatic cell lines and in mouse liver cells. The second is to determine the contributions of each relevant liver receptor to cholesterol removal. This information would be useful in making choices about the most appropriate co therapy, e.g., a statin. Third, we will show that SOF increases the transfer of cholesterol from macrophages, an important cell type in all stages of atherosclerosis, to the liver for disposal. Lastly, we will show that SOF reverses atherosclerosis in mice. Completion of these objectives would pave the way to future studies in non human primates and ultimately in high risk patients with atherosclerosis. Methods: Radio trace cholesterol uptake and removal by liver cells in response to SOF; use chromatographic methods to show in cells and mice that SOF promotes conversion of macrophage-cholesterol to water-soluble bile salts that enter the intestine for disposal; characterize in mice the changes in response to SOF in the quantity and quality of arterial lesions by chemical analysis and morphometry.
期刊论文(63)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
Role of cysteine residues in human plasma phospholipid transfer protein.
半胱氨酸残基在人血浆磷脂转移蛋白中的作用。
DOI:
10.1023/a:1020628006453
发表时间:
1999
期刊:
Journal of protein chemistry
影响因子:
--
作者:
[Qu,SJ, Fan,HZ, Kilinc,C, Pownall,HJ]
通讯作者:
Pownall,HJ
Enhancing reverse cholesterol transport: the case for phosphatidylcholine therapy.
增强反向胆固醇转运:磷脂酰胆碱治疗的案例。
DOI:
10.1097/01.mol.0000169345.15450.4b
发表时间:
2005
期刊:
Current opinion in lipidology
影响因子:
4.4
作者:
[Pownall,HenryJ, Ehnholm,Christian]
通讯作者:
Ehnholm,Christian
DOI:
10.1016/j.jacl.2013.05.004
发表时间:
2013-11
期刊:
Journal of clinical lipidology
影响因子:
4.4
作者:
[Vasudevan M, Tchoua U, Gillard BK, Jones PH, Ballantyne CM, Pownall HJ]
通讯作者:
Pownall HJ
Pro-apoptotic low-density lipoprotein subfractions in type II diabetes.
II 型糖尿病中促凋亡的低密度脂蛋白亚组分。
DOI:
10.1016/j.atherosclerosis.2006.08.059
发表时间:
2007
期刊:
Atherosclerosis
影响因子:
5.3
作者:
[Yang,Chao-yuh, Chen,Hsin-Hung, Huang,MaxT, Raya,JoeL, Yang,Jun-Hai, Chen,Chu-Huang, Gaubatz,JohnW, Pownall,HenryJ, Taylor,AddisonA, Ballantyne,ChristieM, Jenniskens,FloorA, Smith,CharlesV]
通讯作者:
Smith,CharlesV
Regulation of acyl-coenzyme A:cholesterol acyltransferase (ACAT) synthesis, degradation, and translocation by high-density lipoprotein(2) at a low concentration.
低浓度高密度脂蛋白 (2) 对酰基辅酶 A:胆固醇酰基转移酶 (ACAT) 合成、降解和易位的调节。
DOI:
10.1161/01.atv.20.12.2636
发表时间:
2000
期刊:
Arteriosclerosis, thrombosis, and vascular biology
影响因子:
--
作者:
[Li,L, Pownall,HJ]
通讯作者:
Pownall,HJ
共 29 条
Atheroprotection via Reduced Plasma High Density Lipoprotein-Free Cholesterol Bioavailability
-
批准号:10523525
-
项目类别:
-
资助金额:$40.38万
-
财政年份:2019
-
负责人:Henry J. Pownall
-
依托单位:
Atheroprotection via Reduced Plasma High Density Lipoprotein-Free Cholesterol Bioavailability
-
批准号:10063905
-
项目类别:
-
资助金额:$40.38万
-
财政年份:2019
-
负责人:Henry J. Pownall
-
依托单位:
Atheroprotection via Reduced Plasma High Density Lipoprotein-Free Cholesterol Bioavailability
-
批准号:10308045
-
项目类别:
-
资助金额:$40.38万
-
财政年份:2019
-
负责人:Henry J. Pownall
-
依托单位:
High Density Lipoprotein Biogenesis and Speciation
-
批准号:9164514
-
项目类别:
-
资助金额:$60.06万
-
财政年份:2016
-
负责人:Henry J. Pownall
-
依托单位:
High Density Lipoprotein Biogenesis and Speciation
-
批准号:9321088
-
项目类别:
-
资助金额:$58.06万
-
财政年份:2016
-
负责人:Henry J. Pownall
-
依托单位:
LDL
-
批准号:8361060
-
项目类别:
-
资助金额:$1.23万
-
财政年份:2011
-
负责人:Henry J. Pownall
-
依托单位:
HDL WITH SOF
-
批准号:8361103
-
项目类别:
-
资助金额:$0.49万
-
财政年份:2011
-
负责人:Henry J. Pownall
-
依托单位:
LDL
-
批准号:8168530
-
项目类别:
-
资助金额:$2.15万
-
财政年份:2010
-
负责人:Henry J. Pownall
-
依托单位:
HDL WITH SOF
-
批准号:8168595
-
项目类别:
-
资助金额:$2.15万
-
财政年份:2010
-
负责人:Henry J. Pownall
-
依托单位:
HDL WITH SOF
-
批准号:7953809
-
项目类别:
-
资助金额:$1.74万
-
财政年份:2008
-
负责人:Henry J. Pownall
-
依托单位:
LDL
-
批准号:7953758
-
项目类别:
-
资助金额:$1.74万
-
财政年份:2008
-
负责人:Henry J. Pownall
-
依托单位:
HDL AND SOF
-
批准号:7721130
-
项目类别:
-
资助金额:$1.62万
-
财政年份:2007
-
负责人:Henry J. Pownall
-
依托单位:
LDL
-
批准号:7598586
-
项目类别:
-
资助金额:$1.63万
-
财政年份:2006
-
负责人:Henry J. Pownall
-
依托单位:
LDL
-
批准号:7357778
-
项目类别:
-
资助金额:$1.51万
-
财政年份:2005
-
负责人:Henry J. Pownall
-
依托单位:
LDL
-
批准号:7181082
-
项目类别:
-
资助金额:$1.85万
-
财政年份:2004
-
负责人:Henry J. Pownall
-
依托单位:
LDL
-
批准号:6980390
-
项目类别:
-
资助金额:$2.17万
-
财政年份:2003
-
负责人:Henry J. Pownall
-
依托单位:
ALCOHOL & DIETARY HYPERTRIGLYCERIDEMIA
-
批准号:6421254
-
项目类别:
-
资助金额:$15.58万
-
财政年份:2000
-
负责人:Henry J. Pownall
-
依托单位:
ALCOHOL & DIETARY HYPERTRIGLYCERIDEMIA
-
批准号:6306223
-
项目类别:
-
资助金额:$3.6万
-
财政年份:1999
-
负责人:Henry J. Pownall
-
依托单位:
ALCOHOL & DIETARY HYPERTRIGLYCERIDEMIA
-
批准号:6264737
-
项目类别:
-
资助金额:$3.6万
-
财政年份:1998
-
负责人:Henry J. Pownall
-
依托单位:
Lipid Transfer Mechanisms
-
批准号:6434243
-
项目类别:
-
资助金额:$36.36万
-
财政年份:1997
-
负责人:Henry J. Pownall
-
依托单位:
海外基金